MedPath

Peanuts Second Meal Glycemic Response

Not Applicable
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Dietary Supplement: Whole peanuts without skins, Peanut butter, or no peanuts (control)
Registration Number
NCT01413126
Lead Sponsor
Federal University of Vicosa
Brief Summary

Nut consumption is associated with reduced risk of Type 2 diabetes. The aim of this study was to assess the effects of peanut (whole or peanut butter) to breakfast meals on glycemic, insulinemic and selected gut hormone responses, appetite, and food intake over two consecutive meals in obese women with high Type 2 diabetes risk. Fifteen women participated in a randomized crossover trial where 42.5g of whole peanuts (P), peanut butter (PB), or no peanuts (control-C) were added to a 75g available carbohydrate-matched breakfast meal. Postprandial concentrations of blood glucose, insulin, non-esterified free fatty acids (NEFA), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), appetitive sensations and food intake were assessed after breakfast treatments and a standard lunch (75g available carbohydrate).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
15
Inclusion Criteria
  • Body mass index between 30 - 35 kg/M2
  • Not taking medications known to affect glycemia, fat metabolism, or appetite
  • Regular breakfast consumer (≥100 kilocalories ingested within 2 hours of waking on ≥4d/wk)
  • No body weight fluctuation (<5kg in the past 3 months)
  • Willingness to eat all test foods
  • No self-reported allergy to the foods provided in the study
  • No self-reported sleep disorders
  • At least one of the following conditions: waist circumference ≥ 88 cm; reported family history of Type 2 diabetes in first degree relatives; capillary glycemia between 5.5 - 7.0 mmol/L; and/or a 2-hour blood glucose of 7.8 - 11.1 mmol/L (impaired glucose tolerance)
Exclusion Criteria
  • Type 2 diabetes mellitus
  • Dyslipidemia
  • High blood pressure

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Peanut butterWhole peanuts without skins, Peanut butter, or no peanuts (control)42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
Whole peanutWhole peanuts without skins, Peanut butter, or no peanuts (control)42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
No peanuts (control)Whole peanuts without skins, Peanut butter, or no peanuts (control)-
Primary Outcome Measures
NameTimeMethod
Change from baseline in glucose homeostasis at eight hoursBaseline (-10), 15, 45, 60, 90, 120, 180, 240, 265, 295, 310, 340, 370, 430 and 490 minutes

Postprandial concentrations and incremental area under the curve of blood glucose, insulin and glucagon-like peptide-1, and incremental area above the curve of non-esterified free fatty acids were assessed after breakfast treatments and a standard lunch

Secondary Outcome Measures
NameTimeMethod
Change from baseline in incretin hormones at four hoursBaseline (-10), 15, 45, 60, 90, 120, 180 and 240 minutes

Postprandial concentrations and the incremental area under the curve of peptide YY and cholecystokinin were assessed after breakfast treatments

Change in food intake over 24 hours24 hours

All food consumed in laboratory and after leaving the laboratory in the experiment day were recorded

Change from baseline in appetitive sensations at twelve hoursBaseline (-10), 15, 45, 60, 90, 120, 180, 240, 265, 295, 310, 340, 370, 430, 490, 550, 610, 670 and 730 minutes

Appetite ratings were scored at baseline and in a pre-determined times on a 100 mm visual analogue scale anchored with descriptors of "not at all" and "extremely"

Trial Locations

Locations (1)

Federal University of Viçosa

🇧🇷

Viçosa, Minas Gerais, Brazil

© Copyright 2025. All Rights Reserved by MedPath